May 16, 2026

Foundayo Week 5 IQVIA 10,248 Scripts, Hims 125K Wegovy Shipments, Daraxonrasib NEJM PDAC, FDA AI Inspection Pilot, Peptide Cancer Vaccine Reviews

Foundayo Week 5 IQVIA 10,248 (+40% w/w), Hims 125K Wegovy shipments, daraxonrasib NEJM PDAC, FDA AI inspection pilot, peptide cancer vaccine reviews.

10 stories · Covering industry, clinical-trials, regulatory, research

Editor's Note

Post-ECO weekend cycle anchored on the Foundayo Week 5 IQVIA tracker, released through Citi on May 15: 10,248 prescriptions in the week ending May 8, up 40% week-over-week from Week 4's 7,335. The acceleration aligns with the mid-May commercial access expansion at two of the three largest US PBMs that Lilly executives flagged on the Q1 call. Citi maintained $146M Q2 and $1.6B full-year 2026 estimates. On the Hims side, the company disclosed in post-Q1 commentary that it has fulfilled 125,000 Wegovy shipments in the six weeks since the Novo Nordisk branded-distribution deal went live March 26 — a more-encouraging operational signal than the headline Q1 print suggested, even as JPMorgan trimmed its price target on the margin compression. On the non-GLP-1 side, the NEJM May 2026 publication of daraxonrasib (Revolution Medicines' RAS(ON) inhibitor for RAS-mutated pancreatic cancer) used a peptidyl-prolyl isomerase mechanism — cyclophilin A as molecular glue — to achieve 35% objective response in 26 G12-mutated patients with 13.1-month median overall survival. FDA announced an AI-Informed Inspection Pilot on May 15 to apply machine-learning analysis to facility inspections, including peptide-manufacturing sites. Three peptide cancer vaccine reviews landed in May journals: International Journal of Peptide Research and Therapeutics (engineering immune precision against tumor evolution), WIRES Nanomedicine (Garland 2026 review of peptide vaccine materials, targeting, and delivery), and a 2026 Science Advances paper showing single-peptide orientation engineering significantly enhances T-cell responses. Sandoz's Canadian generic semaglutide commercial launch readiness for Q3 2026 came into sharper focus as Health Canada continued reviewing the seven remaining generic submissions filed after the April 28 Dr. Reddy's and May 1 Apotex approvals.

Industry

Foundayo Week 5 IQVIA Tracker (May 15 Citi Note): 10,248 Prescriptions Up 40% W/W from 7,335 in Week 4

Citi's Friday May 15 client note reported Foundayo (orforglipron) hit 10,248 US prescriptions in the week ending May 8 per IQVIA — the first 40% week-over-week jump in the launch series. Week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5). The acceleration aligns with mid-May commercial access activation at two of the three largest US PBMs that Lilly flagged on the April 30 Q1 call. Citi maintained $146M Q2 revenue and $1.6B full-year 2026 estimates. The Wegovy pill remains ahead — Novo CEO Doustdar's May 14 commentary confirmed >1M cumulative US users since the January 5 launch — but the gap is narrowing as Foundayo's PBM coverage comes online and telehealth volume (~35% of total per Lilly executives, not captured in retail-only IQVIA data) layers on top.

#foundayo #orforglipron #iqvia #citi #week-5 #eli-lilly #pbm-access

Industry

Hims & Hers Fulfilled 125,000 Wegovy Shipments in Six Weeks Since Novo Nordisk Branded Deal Went Live March 26

Hims & Hers disclosed in post-Q1 commentary picked up by Stocktwits and Yahoo Finance that the company has fulfilled approximately 125,000 Wegovy shipments since the Novo Nordisk branded-distribution partnership activated on March 26, 2026 — roughly 21,000 per week in operational terms. The volume signals materially stronger Wegovy uptake through the Hims platform than the Q1 print's $608M revenue figure suggested, with most of the contribution landing in Q2 books. Subscriber count held at 2.6M (+9% YoY), monthly average revenue per subscriber dropped to $80 from $85 on the product-mix shift, and full-year guidance was raised to $2.8-3.0B revenue. Deutsche Bank's George Hill trimmed his target to $25 from $28 (Hold). The 'Netflix of healthcare' framing from major investor Cathie Wood persists despite the post-print drop; HIMS shares partially recovered to $29.14 in early-week trading.

#hims-hers #wegovy #novo-nordisk #branded-distribution #shipments #q1-2026

Clinical Trials

Daraxonrasib NEJM Publication (May 2026): Revolution Medicines' RAS(ON) Inhibitor Hit 35% ORR + 13.1-Month OS in RAS G12-Mutated Pancreatic Cancer Phase 1/2

The New England Journal of Medicine published Revolution Medicines' daraxonrasib (RMC-6236) Phase 1/2 data in previously treated advanced RAS-mutated pancreatic adenocarcinoma in May 2026. In the subgroup of 26 patients with G12 mutations treated at the 300 mg dose, objective response rate hit 35% with median progression-free survival 8.5 months and median overall survival 13.1 months — outcomes meaningfully better than the historical 5-month median OS in second-line PDAC. The mechanism is unusual: daraxonrasib is an oral small molecule that acts as a molecular glue, recruiting the peptidyl-prolyl isomerase cyclophilin A to form a tri-complex with active GTP-bound mutant RAS, blocking effector binding and downstream signaling. The drug targets KRAS, HRAS, and NRAS in the on-state — a mechanistically distinct approach from Chugai's LUNA18 cyclic peptide RAS inhibitor. FDA granted Expanded Access. The cyclophilin A-mediated mechanism puts peptidyl-prolyl chemistry at the center of a major oncology readout.

#daraxonrasib #rmc-6236 #revolution-medicines #ras-mutation #cyclophilin-a #pancreatic-cancer #nejm

Regulatory

FDA Announces AI-Informed Inspection Pilot (May 15) — Will Apply Machine Learning to Facility Inspections Including Peptide Manufacturing

The FDA announced an AI-Informed Inspection Pilot on May 15, 2026, applying machine-learning analysis to facility inspection prioritization and execution. The program is part of the FDA's Pharmaceutical Quality/Manufacturing Standards initiative and will affect peptide-manufacturing sites including 503A compounding pharmacies, 503B outsourcing facilities, and full-scale peptide CDMOs. AI inputs include historical inspection findings, FAERS adverse-event signals, supply-chain risk indicators, and recall history. The pilot lands during a sensitive compounding-pharmacy regulatory cycle ahead of the July 23-24 PCAC meeting on seven peptides for 503A bulks-list inclusion (BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, Epitalon) and against the April 30 503B bulks-list proposal closing comments June 29. Industry response is mixed: faster inspection cycles could ease compliance burden for well-run facilities but may concentrate enforcement on the gray-market segment.

#fda #ai-inspection #peptide-cdmo #compounding #pcac #facility-inspection

Research

International Journal of Peptide Research and Therapeutics (May 2026): Peptide-Based Cancer Vaccines Review — Engineering Immune Precision Against Tumor Evolution

A review article published in the International Journal of Peptide Research and Therapeutics in May 2026 consolidates the current state of peptide-based cancer vaccines, covering antigen selection, adjuvant chemistry, and delivery platforms designed to address tumor evolution and immune escape. The review argues that despite persistent challenges around peptide stability and limited immunogenicity, the combination of nanomaterials and adjuvants has significantly enhanced immune response efficiency and targeted delivery — with applications in drug-resistant and metastatic cancers. The piece sits alongside two other May peptide vaccine reviews (WIRES Nanomedicine, Science Advances) and frames the ASCO 2026 peptide-oncology slate (BioVaxys MVP-S, BriaCell Bria-IMT, Evaxion EVX-01) as the clinical pipeline backing the review-paper momentum.

#peptide-vaccine #cancer-immunotherapy #tumor-evolution #international-journal-of-peptide-research #nanomaterials #review-article

Research

Science Advances 2026: Peptide Cancer Vaccine Orientation Study Shows Single-Peptide Placement Significantly Enhances T-Cell Response

A 2026 Science Advances paper demonstrated that systematically changing the orientation and placement of a single cancer-targeting peptide within a vaccine construct leads to formulations that significantly enhance immune response. One specific vaccine design consistently outperformed others by shrinking tumors, extending animal survival, and generating larger numbers of highly active cancer-killing T-cells. The work is mechanistically important for the broader personalized neoantigen vaccine pipeline (Mount Sinai PGV001, BioNTech autogene cevumeran, Evaxion EVX-01) because peptide-orientation engineering has been an under-systematized variable in current vaccine designs. The findings provide a generalizable engineering principle that could inform second-generation neoantigen vaccine constructs heading into late 2026 and 2027.

#peptide-vaccine #cancer-immunotherapy #science-advances #orientation #neoantigen #t-cell-response

Research

WIRES Nanomedicine 2026 Review (Garland et al.): Peptide-Based Cancer Vaccines Materials, Targeting, and Delivery Strategies

A WIRES Nanomedicine and Nanobiotechnology 2026 review by Garland and colleagues synthesizes the materials-science side of peptide-based cancer vaccine development: lipid nanoparticle delivery, dendrimer scaffolds, peptide self-assembly platforms, and adjuvant chemistry. The piece complements the broader review wave by focusing on delivery and formulation rather than antigen selection. Key themes: lipid-nanoparticle-encapsulated peptides show improved bioavailability and immune-cell uptake versus free peptides; self-assembling peptide hydrogels enable sustained antigen release at injection site; CpG and TLR agonist combinations remain the dominant adjuvant approach but with new variants emerging. The review positions peptide vaccines as catching up to mRNA cancer vaccines (BioNTech, Moderna programs) on delivery sophistication.

#peptide-vaccine #cancer-immunotherapy #lipid-nanoparticles #drug-delivery #wires-nanomedicine #review-article

Research

EASO Framework US Implementation Reception — Endocrinology Society Response Awaited as First-Line GLP-1 Algorithm Lands

The EASO 2026 Nature Medicine framework published May 14, presented at ECO 2026 — formally privileging semaglutide and tirzepatide as first-line therapy across most obesity complications with differentiated complication-specific recommendations — has generated initial reception coverage. The Endocrine Society and American Diabetes Association haven't yet issued formal endorsement or counter-response statements as of May 16, though informal commentary from US endocrinologists has been broadly favorable. The framework's main US-specific gap is its silence on cost and insurance access — the algorithm assumes prescribers can choose between semaglutide and tirzepatide based on clinical indication, but US patients without diabetes face the Medicare Part D weight-loss-only exclusion. The Medicare GLP-1 Bridge launching July 1, 2026 partly addresses that gap; broader integration awaits CMS rulemaking. ADA 2026 Scientific Sessions in New Orleans June 5-8 will be the next inflection point for guideline alignment between US and EASO positions.

#easo #endocrine-society #ada-2026 #guidelines #first-line-therapy #semaglutide #tirzepatide

Industry

Sandoz Q3 2026 Canadian Generic Semaglutide Commercial Launch Readiness in Focus After Health Canada Multi-Manufacturer Approval Sequence

Sandoz Group AG's preparations for a Q3 2026 Canadian commercial launch of generic semaglutide came into sharper focus over the weekend as Health Canada continues reviewing seven remaining generic submissions filed after the April 28 Dr. Reddy's and May 1 Apotex approvals. Sandoz signaled in late 2024 it would launch a Canadian generic semaglutide in 2026 when the active-drug patent expired; the company's filing is currently under Health Canada review with commercial readiness contingent on the agency's review timeline. Industry analysts expect Sandoz to enter the Canadian market with pricing 45-90% below the brand Ozempic CAD $300-400/month range, putting Sandoz generic pricing in the CAD $30-200/month tier (~$22-145 USD/month). The Canadian generic market is a five-year preview of what will hit the US after December 2031 patent expiry; watch what Ontario, BC, and Quebec formulary committees decide on listing terms over the next 90 days.

#sandoz #generic-semaglutide #health-canada #q3-2026 #canada #patent-expiry

Industry

Lilly Foundayo + LillyDirect Telehealth Stack: 35% of Launch Volume via Mid-Channel Distribution Per Q1 Commentary

Eli Lilly executives' Q1 commentary clarified the Foundayo launch-channel mix: roughly 45% via LillyDirect (the company's direct-to-patient pharmacy), 35% via telehealth platforms not captured in retail-only IQVIA data, and 20% via traditional retail pharmacy fills. The split helps explain the apparent gap between Citi's IQVIA-reported 10,248 Week 5 prescriptions and the 20,000+ patient count Lilly disclosed on the April 30 Q1 call. The pattern suggests Foundayo is being adopted preferentially through digitally-enabled care channels — Hims & Hers, LifeMD, JoinFound, and other telehealth platforms with weight-management Rx infrastructure — rather than primary-care prescribing. The mix is structurally similar to the Wegovy pill launch but with a higher telehealth share. The implication for the next 90 days: PBM coverage expansion (mid-May) and brand-name TV advertising (launching late May per the Q1 commentary) will drive most of the next leg of growth.

#foundayo #lillydirect #telehealth #channel-mix #iqvia #eli-lilly